This HTML5 document contains 39 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n18http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n14http://linked.opendata.cz/resource/domain/vavai/subjekt/
n13http://linked.opendata.cz/ontology/domain/vavai/
n10http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00064173%3A_____%2F12%3A43906998%21RIV13-MZ0-00064173/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n17http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n8http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n16http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n12http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00064173%3A_____%2F12%3A43906998%21RIV13-MZ0-00064173
rdf:type
n13:Vysledek skos:Concept
dcterms:description
Relapse risk assessment and individual treatment recommendations remain suboptimal for breast cancer patients. In the light of existing preclinical and clinical data, we studied NT5E (5'-nucleotidase, ecto) expression and NT5E CpG island methylation in breast cancer. METHODS: We used RT-PCR, qPCR, methylation-specific PCR and pyrosequencing to analyse NT5E in breast carcinoma cell lines and primary and breast carcinomas. RESULTS: NT5E CpG island methylation was inversely associated with NT5E expression in breast carcinoma cell lines. In clinical series, patients whose primary tumours had NT5E CpG island methylation were less likely to develop metastasis (P = 0.003, OR = 0.34, 95% CI: 0.17-0.69). In 3/4 paired samples, NT5E was methylated in primary tumours and demethylated in CNS metastases. Patients progressing to non-visceral as compared with visceral metastases were more likely to have NT5E CpG island methylation in primary tumours (P = 0.01, OR = 11.8). Patients with tumours lacking detectable methylation had shorter disease-free survival (DFS) (P = 0.001, HR = 2.7) and overall survival (OS) (P 0.001, HR 3). The favourable prognostic value of NT5E methylation was confirmed in oestrogen receptor negative (P = 0.011, HR = 3.27, 95% CI: 1.31-8.12) and in triple negative cases (P = 0.004; HR = 6.2, 95% CI: 1.9-20). Moreover, we observed a more favourable outcome to adjuvant chemotherapy in patients whose tumours were positive for NT5E CpG island methylation: DFS (P = 0.0016, HR = 5.1, 95% CI: 1.8-14.37) and OS (P = 0.0005, HR = 7.4, 95% CI: 2.416-23.08). CONCLUSION: NT5E CpG island methylation is a promising breast cancer biomarker. Relapse risk assessment and individual treatment recommendations remain suboptimal for breast cancer patients. In the light of existing preclinical and clinical data, we studied NT5E (5'-nucleotidase, ecto) expression and NT5E CpG island methylation in breast cancer. METHODS: We used RT-PCR, qPCR, methylation-specific PCR and pyrosequencing to analyse NT5E in breast carcinoma cell lines and primary and breast carcinomas. RESULTS: NT5E CpG island methylation was inversely associated with NT5E expression in breast carcinoma cell lines. In clinical series, patients whose primary tumours had NT5E CpG island methylation were less likely to develop metastasis (P = 0.003, OR = 0.34, 95% CI: 0.17-0.69). In 3/4 paired samples, NT5E was methylated in primary tumours and demethylated in CNS metastases. Patients progressing to non-visceral as compared with visceral metastases were more likely to have NT5E CpG island methylation in primary tumours (P = 0.01, OR = 11.8). Patients with tumours lacking detectable methylation had shorter disease-free survival (DFS) (P = 0.001, HR = 2.7) and overall survival (OS) (P 0.001, HR 3). The favourable prognostic value of NT5E methylation was confirmed in oestrogen receptor negative (P = 0.011, HR = 3.27, 95% CI: 1.31-8.12) and in triple negative cases (P = 0.004; HR = 6.2, 95% CI: 1.9-20). Moreover, we observed a more favourable outcome to adjuvant chemotherapy in patients whose tumours were positive for NT5E CpG island methylation: DFS (P = 0.0016, HR = 5.1, 95% CI: 1.8-14.37) and OS (P = 0.0005, HR = 7.4, 95% CI: 2.416-23.08). CONCLUSION: NT5E CpG island methylation is a promising breast cancer biomarker.
dcterms:title
NT5E CpG island methylation is a favourable breast cancer biomarker NT5E CpG island methylation is a favourable breast cancer biomarker
skos:prefLabel
NT5E CpG island methylation is a favourable breast cancer biomarker NT5E CpG island methylation is a favourable breast cancer biomarker
skos:notation
RIV/00064173:_____/12:43906998!RIV13-MZ0-00064173
n13:predkladatel
n14:ico%3A00064173
n3:aktivita
n11:I
n3:aktivity
I
n3:cisloPeriodika
1
n3:dodaniDat
n12:2013
n3:domaciTvurceVysledku
n18:1293354
n3:druhVysledku
n9:J
n3:duvernostUdaju
n16:S
n3:entitaPredkladatele
n10:predkladatel
n3:idSjednocenehoVysledku
154929
n3:idVysledku
RIV/00064173:_____/12:43906998
n3:jazykVysledku
n7:eng
n3:klicovaSlova
triple-negative breast cancer; epigenetics; metastasis; breast cancer
n3:klicoveSlovo
n8:breast%20cancer n8:epigenetics n8:triple-negative%20breast%20cancer n8:metastasis
n3:kodStatuVydavatele
GB - Spojené království Velké Británie a Severního Irska
n3:kontrolniKodProRIV
[847E6CAF2E2B]
n3:nazevZdroje
British Journal of Cancer
n3:obor
n15:FD
n3:pocetDomacichTvurcuVysledku
1
n3:pocetTvurcuVysledku
20
n3:rokUplatneniVysledku
n12:2012
n3:svazekPeriodika
107
n3:tvurceVysledku
Gojiš, Ondřej
n3:wos
000305888400012
s:issn
0007-0920
s:numberOfPages
9
n17:doi
10.1038/bjc.2012.212